Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.
Wayham NP, Niedecken AR, Simons JF, Chiang YY, Medina-Cucurella AV, Mizrahi RA, Wagner EK, Gras A, Segal I, Witte P, Enstrom A, Bountouvas A, Nelson SM, Weinberger T, Tan D, Asensio MA, Subramanian A, Lim YW, Adler AS, Keating SM. Wayham NP, et al. Among authors: enstrom a. J Infect Dis. 2023 Aug 31;228(5):555-563. doi: 10.1093/infdis/jiad102. J Infect Dis. 2023. PMID: 37062677 Free PMC article.
A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.
Davies R, Peng SL, Lickliter J, McLendon K, Enstrom A, Chunyk AG, Blanchfield L, Wang N, Blair T, Thomas HM, Smith A, Dillon SR. Davies R, et al. Among authors: enstrom a. Clin Transl Sci. 2024 Nov;17(11):e70055. doi: 10.1111/cts.70055. Clin Transl Sci. 2024. PMID: 39494621 Free PMC article. Clinical Trial.
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.
Cavalcante L, Chandana S, Lakhani N, Enstrom A, LeBlanc H, Schmalz J, Lengyel K, Schneider F, Thomas H, Chisamore MJ, Peng SL, Naumovski A, Davar D. Cavalcante L, et al. Among authors: enstrom a. J Immunother Cancer. 2024 Aug 13;12(8):e009475. doi: 10.1136/jitc-2024-009475. J Immunother Cancer. 2024. PMID: 39142718 Free PMC article.
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).
Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, Voskoboynik M, Sanborn RE, Grewal JS, Narayan A, Patnaik A, Gainor JF, Sznol M, Enstrom A, Blanchfield L, LeBlanc H, Thomas H, Chisamore MJ, Peng SL, Naumovski A. Davar D, et al. Among authors: enstrom a. J Immunother Cancer. 2024 Aug 3;12(8):e009474. doi: 10.1136/jitc-2024-009474. J Immunother Cancer. 2024. PMID: 39097413 Free PMC article. Clinical Trial.
33 results